Privia Health Group, Inc. (NASDAQ:PRVA – Get Free Report) CFO David Mountcastle sold 3,445 shares of Privia Health Group stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $80,371.85. Following the completion of the transaction, the chief financial officer now directly owns 176,231 shares of the company’s stock, valued at approximately $4,111,469.23. This trade represents a 1.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
David Mountcastle also recently made the following trade(s):
- On Wednesday, April 2nd, David Mountcastle sold 5,630 shares of Privia Health Group stock. The shares were sold at an average price of $22.38, for a total value of $125,999.40.
Privia Health Group Trading Up 1.8 %
PRVA opened at $23.32 on Friday. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $26.04. The company has a market cap of $2.83 billion, a P/E ratio of 233.22, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88. The company has a fifty day moving average price of $23.50 and a two-hundred day moving average price of $22.10.
Institutional Investors Weigh In On Privia Health Group
Analyst Ratings Changes
A number of research analysts recently commented on the stock. Piper Sandler upped their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Truist Financial upped their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a “buy” rating in a research report on Thursday, April 10th. Canaccord Genuity Group lifted their price target on Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Robert W. Baird raised their price objective on Privia Health Group from $24.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, April 15th. Finally, Barclays raised their price target on shares of Privia Health Group from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.38.
View Our Latest Research Report on Privia Health Group
About Privia Health Group
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
Read More
- Five stocks we like better than Privia Health Group
- Investing In Automotive Stocks
- Magnificent 7 Stocks Send a Dire Warning to Markets
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Spotify Stock Still Has Room to Run in 2025
- The 3 Best Blue-Chip Stocks to Buy Now
- Buy the Dip: Top Tech Stocks Analysts Say Are Undervalued
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.